Albumin removal from human fibrinogen preparations for manufacturing human fibrin-based biomaterials.

Autor:	Sharma V; RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood HA6 2RN, UK.; Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK., Patel N; RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood HA6 2RN, UK., Dye JF; RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood HA6 2RN, UK., Hook L; RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood HA6 2RN, UK., Mason C; Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK., García-Gareta E; RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood HA6 2RN, UK.
Jazyk:	angličtina
Zdroj:	Biochimie open [Biochim Open] 2015 Jun 06; Vol. 1, pp. 6-10. Date of Electronic Publication: 2015 Jun 06 (Print Publication: 2015).
DOI:	10.1016/j.biopen.2015.05.002
Abstrakt:	Commercially available two component human fibrin sealants are commonly used to manufacture human fibrin-based biomaterials. However, this method is costly and allows little room for further tuning of the biomaterial. Human fibrinogen solutions offer a more cost-effective and versatile alternative to manufacture human fibrin-based biomaterials. Yet, human fibrinogen is highly unstable and contains certain impurities like human albumin. Within the context of biomaterials and tissue engineering we offer a simple yet novel solution based on classical biochemical techniques to significantly reduce albumin in human fibrinogen solutions. This method can be used for various tissue engineering and biomedical applications as an initial step in the manufacturing of human fibrin-based biomaterials to optimise their regenerative application.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu